Summary

The incidence of invasive fungal infections has increased during the past 20 years in pediatric patients, with immunocompromised patients at an increased risk. Data from 2 studies that evaluated the safety and efficacy of voriconazole in pediatric patients with invasive candidiasis, esophageal candidiasis, and invasive aspergillosis.